SAB Biotherapeutics's total assets for Q1 2025 were $38.12M, a decrease of -13.75% from the previous quarter. SABS total liabilities were $16.71M for the fiscal quarter, a -8.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.